Drugs / IBI130
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05923008 | Nov 2023 → Nov 2024 overdue | neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05923008 ↗ |